NCT00220701

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: St. Luke's-Roosevelt Hospital Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase. It is hypothesized that Escitalopram will be superior to placebo in improving depression, as well as psychosocial, temperamental, and cognitive functioning.

Detailed description

This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of Dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase. Flexible dosing to a maximum of 40 mg per day will be used. It is hypothesized that Escitalopram will be superior to placebo in improving depression, as well as psychosocial, temperamental, and cognitive functioning. Blood cytokine levels will also be measured at weeks 0, 12, and 24 to determine their relationship to depressive symptoms and improvement.

Conditions

• Dysthymic Disorder

Interventions

Type	Name	Description
DRUG	Lexapro (escitalopram)	antidepressant drug selective serotonin reuptake inhibitor (SSRI)

Timeline

• Start date: 2002-06-01
• Primary completion: 2008-11-01
• Completion: 2009-01-01
• First posted: 2005-09-22
• Last updated: 2015-11-11
• Results posted: 2014-11-25

Locations

1 site across 1 country: United States